Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2004 02:08 ET | Source: Crucell N.V.

Galapagos appoints Raj Parekh as Chairman and Wilson Totten to Board of Directors

MECHELEN, Belgium and LEIDEN, The Netherlands, Oct. 5, 2004 (PRIMEZONE) -- Galapagos Genomics NV announced that it has appointed Raj Parekh, Ph.D. as Chairman and Wilson Totten, M.D. to the company's...
October 04, 2004 06:05 ET | Source: Crucell N.V.

Aviva / Delta Lloyd Acquires 5.09% Interest in Crucell

LEIDEN, The Netherlands, Oct. 04, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL "(Nasdaq:CRXL) announced today that Aviva plc. / Delta Lloyd Levensverzekering N.V. has...
September 21, 2004 08:08 ET | Source: Crucell N.V.

Crucell to Present at UBS Global Life Sciences Conference, New York, September 28

LEIDEN, Netherlands, Sept. 21, 2004 (PRIMEZONE) -- Crucell N.V. (Euronext, Nasdaq: CRXL) has announced its President and CEO, Ronald Brus, will present at the UBS Global Life Sciences Conference to...
September 14, 2004 02:11 ET | Source: Crucell N.V.

Crucell Grants IAVI Exclusive License to use AdVac Technology for AIDS Vaccine

LEIDEN, The Netherlands, Sept. 14, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell and the International AIDS Vaccine Initiative (IAVI) have signed an exclusive license agreement to develop...
September 13, 2004 08:14 ET | Source: Crucell N.V.

Crucell Announces PER.C6(R) Licensing Agreement with Vaxin for Adenoviral Vaccines

LEIDEN, The Netherlands, Sept. 13, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq:CRXL) announced today that it has signed a non-exclusive PER.C6(R) technology license...
September 08, 2004 02:10 ET | Source: Crucell N.V.

Crucell and DSM Announce PER.C6 Licensing Agreement with MorphoSys for Antibody Production

LEIDEN and SITTARD, The Netherlands, Sept. 8, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
August 31, 2004 10:16 ET | Source: Crucell N.V.

PER.C6(R)-produced HIV Vaccine Progresses Towards Next Phase

LEIDEN, Netherlands, Aug. 31, 2004 (PRIMEZONE) -- At today's AIDS Vaccine 2004 conference in Lausanne, Switzerland, Merck & Co.'s Executive Director for vaccine research Dr. Robin Isaacs...
August 30, 2004 08:07 ET | Source: Crucell N.V.

Crucell and Harvard Medical School Announce Promising Results for Novel Vaccine Technology (AdVac)

LEIDEN, The Netherlands, Aug. 30, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and Harvard Medical School today announced results of a joint study...
August 25, 2004 02:09 ET | Source: Crucell N.V.

Crucell Announces PER.C6 Licensing Agreement with Wyeth Pharmaceuticals

LEIDEN, The Netherlands, Aug. 25, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a PER.C6(R) research license agreement...
August 20, 2004 02:14 ET | Source: Crucell N.V.

Crucell and DSM Announce PER.C6 Licensing Agreement with Synergenics and Synco Bio Partners Investments for Production of Monoclonal Antibodies

LEIDEN, The Netherlands, Aug. 20, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right